Counterfeit risk focus PSI is a non-profit trade association of security directors from 37 international pharmaceutical manufacturers, united to combat counterfeit medicines and protect public health. This positioning highlights a strong emphasis on pharmaceutical integrity and the potential value of enhanced monitoring, threat intelligence, and collaborative defenses for member companies.

Collaboration network PSI actively partners with government agencies, industry groups, and private sector security firms (e.g., IPR Center, BrandShield, SafetyDetectives) to share information and coordinate responses. Sales opportunities exist in expanding fellow member engagement, additional information-sharing platforms, and joint threat-detection services.

Threat intelligence growth Recent initiatives like the Pharma Fraud report and ongoing online threat monitoring indicate demand for comprehensive risk analytics and early-warning systems. There is potential to offer premium analytics, dashboards, and incident response support to enhance PSI’s dissemination and actionability of counterfeit-trade insights.

Global reach and legitimacy With members from 37 international manufacturers and connections to global security ecosystems, PSI presents a gateway to a broad, multinational buyer base. Sales can target member firms as channel partners or direct adopters of scalable security solutions, training, and compliance programs.

Moderate scale, clear budget Reported revenue in the 1–10 million range suggests some budget for security initiatives and partnerships, especially for industry-wide reporting, capacity-building, and information exchange. This indicates openness to scalable, cost-effective solutions and multi-year collaboration opportunities.